CVS HEALTH financials
$87.10−0.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $105.45B | $99.85B | $105.10B | $102.24B | $98.43B | $94.07B | $96.95B | $94.88B | $90.84B | $87.98B | $93.55B | $89.49B |
| Gross profit | $15.11B | $15.05B | $12.97B | $13.17B | $13.11B | $13.88B | $12.14B | $12.01B | $12.99B | $12.11B | $13.61B | $13.30B |
| Gross margin | 14.3% | 15.1% | 12.3% | 12.9% | 13.3% | 14.8% | 12.5% | 12.7% | 14.3% | 13.8% | 14.5% | 14.9% |
| Operating income | $4.06B | $4.11B | $1.52B | -$3.84B | $1.89B | $2.85B | $1.61B | $282.0M | $2.65B | $1.82B | $3.10B | $3.41B |
| Net income | $2.98B | $2.94B | $2.94B | -$3.98B | $1.02B | $1.78B | $1.64B | $87.0M | $1.77B | $1.11B | $2.05B | $2.26B |
| Net margin | 2.8% | 2.9% | 2.8% | −3.9% | 1.0% | 1.9% | 1.7% | 0.1% | 1.9% | 1.3% | 2.2% | 2.5% |
| Diluted EPS | $2.31 | $2.30 | $2.30 | $-3.13 | $0.80 | $1.41 | $1.30 | $0.07 | $1.41 | $0.88 | $1.58 | $1.75 |
| EBITDA | $5.19B | $5.22B | $2.67B | $3.02B | $3.06B | $4.01B | $2.77B | $2.61B | $3.80B | $2.96B | $3.10B | $4.55B |
| Operating cash flow | $6.34B | $4.25B | $3.39B | $796.0M | $1.90B | $4.56B | $1.86B | -$745.0M | $3.09B | $4.90B | -$2.64B | $2.72B |
| Free cash flow | $5.65B | $3.40B | $2.61B | $98.0M | $1.29B | $3.81B | $1.09B | -$1.42B | $2.45B | $4.20B | -$3.55B | $2.17B |
| Diluted shares | 1,287.0M | 1,279.0M | 1,281.0M | 1,269.0M | 1,270.0M | 1,264.0M | 1,263.0M | 1,259.0M | 1,259.0M | 1,267.0M | 1,292.0M | 1,290.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.33B | $9.54B | $8.45B | $9.10B | $11.79B | $10.08B |
| Short-term investments | $2.63B | $2.26B | $2.15B | $2.13B | $2.39B | $2.58B |
| Total debt | $61.41B | $63.11B | $64.57B | $65.84B | $66.49B | $64.71B |
| Total assets | $253.77B | $252.97B | $253.54B | $255.33B | $258.34B | $255.59B |
| Total liabilities | $173.87B | $175.34B | $178.16B | $182.22B | $180.79B | $178.47B |
| Shareholders' equity | $79.90B | $77.64B | $75.38B | $73.11B | $77.55B | $77.11B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology